Arrivent Biopharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 3,182,080 shares, representing 6.8% of the outstanding common stock of Arrivent Biopharma Inc.
NASDAQ
FMR LLC has reported beneficial ownership of 6.8% of Arrivent Biopharma Inc.'s common stock as of March 31, 2026.
NASDAQ
Sofinnova Venture Partners XI and its affiliates have filed an amended Schedule 13G, disclosing a 4.1% beneficial ownership in ArriVent Biopharma, Inc. as of December 31, 2025.
NASDAQ
Hillhouse Investment Management, Ltd. has reported a 9.5% beneficial ownership stake in ArriVent BioPharma, Inc., holding 3,929,117 shares of common stock.
NASDAQ
The Vanguard Group reported a beneficial ownership of 4.52% in ArriVent Biopharma Inc. as of December 31, 2025, following an internal realignment.
NASDAQ
SCHEDULE 13G: BlackRock Discloses 5.6% Stake in Arrivent Biopharma
BlackRock, Inc. has reported a 5.6% beneficial ownership stake in Arrivent Biopharma Inc., holding over 2.3 million common shares as of December 31, 2025.
NASDAQ
Octagon Capital Advisors LP and affiliated funds, along with Ting Jia, have disclosed a passive beneficial ownership of 4.9% in ArriVent BioPharma, Inc.
NASDAQ
FMR LLC and Abigail P. Johnson have reported an 8.4% beneficial ownership stake in Arrivent Biopharma Inc. as of September 30, 2025.
NASDAQ
The Vanguard Group has reported a passive 5% ownership stake in ArriVent Biopharma Inc., holding over 2 million shares of common stock.
NASDAQ
SCHEDULE 13G/A: BlackRock Amends Arrivent BioPharma Stake to 4.9%
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Arrivent BioPharma Inc. common stock.
NASDAQ
HBM Healthcare Investments (Cayman) Ltd. has reported a beneficial ownership of 5.4% in ArriVent BioPharma, Inc., holding 2,195,014 shares of common stock.
NASDAQ
Novo Holdings A/S has disclosed a beneficial ownership of 4.99% of ArriVent BioPharma, Inc.'s common stock, holding 1,872,142 shares.
NASDAQ
Suvretta Capital Management, LLC and its affiliates have disclosed a 9.9% beneficial ownership stake in ArriVent BioPharma, Inc. common stock.
NASDAQ
Infinitum Asset Management and its affiliates have disclosed a 9.99% beneficial ownership stake in ArriVent BioPharma, Inc.'s Common Stock.
NASDAQ
Infinitum Asset Management, along with its related entities, has reported a passive beneficial ownership of 6.1% in ArriVent BioPharma, Inc.'s common stock.
NASDAQ
Novo Holdings A/S, a prominent Danish life sciences investment firm, has disclosed a significant 5.2% beneficial ownership stake in ArriVent BioPharma, Inc., holding 1,750,000 shares of common stock.